{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T23:01:42Z","timestamp":1781218902438,"version":"3.54.1"},"update-to":[{"DOI":"10.1002\/14651858.cd009294.pub2","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2021,6,14]],"date-time":"2021-06-14T00:00:00Z","timestamp":1623628800000}}],"reference-count":85,"publisher":"Wiley","issue":"6","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd009294.pub3","type":"journal-article","created":{"date-parts":[[2021,6,14]],"date-time":"2021-06-14T13:52:23Z","timestamp":1623678743000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Intravesical gemcitabine for non-muscle invasive bladder cancer"],"prefix":"10.1002","volume":"2021","author":[{"given":"Mi Ah","family":"Han","sequence":"additional","affiliation":[{"name":"Department of Preventive Medicine; College of Medicine, Chosun University; Gwangju Korea, South"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Maisch","sequence":"additional","affiliation":[{"name":"Department of Urology; Rechts der Isar Medical Center, Technical University of Munich; Munich Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae Hung","family":"Jung","sequence":"additional","affiliation":[{"name":"Department of Urology; Yonsei University Wonju College of Medicine; Wonju Korea, South"},{"name":"Center of Evidence Based Medicine, Institute of Convergence Science; Yonsei University; Seoul Korea, South"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun Eul","family":"Hwang","sequence":"additional","affiliation":[{"name":"Department of Hematology-Oncology; Chonnam National University Medical School, Chonnam National University Hwasun Hospital; Hwasun Korea, South"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vikram","family":"Narayan","sequence":"additional","affiliation":[{"name":"Department of Urology; University of Minnesota; Minneapolis Minnesota USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Cleves","sequence":"additional","affiliation":[{"name":"Velindre NHS Trust; Cardiff University Library Services; Cardiff UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eu Chang","family":"Hwang","sequence":"additional","affiliation":[{"name":"Department of Urology; Chonnam National University Medical School, Chonnam National University Hwasun Hospital; Hwasun Korea, South"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Dahm","sequence":"additional","affiliation":[{"name":"Urology Section; Minneapolis VA Health Care System; Minneapolis Minnesota USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,6,14]]},"reference":[{"issue":"4","key":"10.1002\/14651858.CD009294.pub3-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1200\/JCO.2008.20.8199","article-title":"Randomized phase III trial on gemcitabine versus mytomicin in recurrent superficial bladder cancer: evaluation of efficacy and tolerance","volume":"28","author":"Addeo","year":"2010","journal-title":"Journal of Clinical Oncology"},{"issue":"14","key":"10.1002\/14651858.CD009294.pub3-BIB0002|cit2","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.ejcsup.2008.06.049","article-title":"Intravesical gemcitabine versus mitomycin for recurrent superficial bladder tumours (stages pTa and pT1): a randomized prospective study","volume":"6","author":"Faiola","year":"2008","journal-title":"European Journal of Cancer Supplements"},{"issue":"15 Suppl","key":"10.1002\/14651858.CD009294.pub3-BIB0003|cit3","doi-asserted-by":"publisher","first-page":"5075","DOI":"10.1200\/jco.2008.26.15_suppl.5075","article-title":"Intravesical gemcitabine versus mitomycin for recurrent superficial bladder tumors (stages pTa and pT1): a randomized prospective study","volume":"26","author":"Montella","year":"2008","journal-title":"Journal of Clinical Oncology"},{"issue":"4s","key":"10.1002\/14651858.CD009294.pub3-BIB0004|cit4","doi-asserted-by":"publisher","first-page":"e664","DOI":"10.1016\/j.juro.2011.02.1765","article-title":"Intravesical gemcitabine versus Bacillus Calmette-Guerin (BCG) in treatment of non-muscle invasive bladder cancer: short term comparative study","volume":"185","author":"Bendary","year":"2011","journal-title":"Journal of Urology"},{"issue":"4s","key":"10.1002\/14651858.CD009294.pub3-BIB0005|cit5","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/S0022-5347(09)61930-3","article-title":"Single postoperative instillation of gemcitabine in patients with superficial transitional cell carcinoma of the bladder: a randomised, double-blind, placebo-controlled phase 3 multicenter study","volume":"181","author":"B\u00f6hle","year":"2009","journal-title":"Journal of Urology"},{"issue":"3","key":"10.1002\/14651858.CD009294.pub3-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.eururo.2009.06.010","article-title":"Single postoperative instillation of gemcitabine in patients with non-muscle-invasive transitional cell carcinoma of the bladder: a randomised, double-blind, placebo-controlled phase III multicentre study","volume":"56","author":"B\u00f6hle","year":"2009","journal-title":"European Urology"},{"key":"10.1002\/14651858.CD009294.pub3-BIB0007|cit7","unstructured":"Instillation of gemcitabine in patients with superficial bladder cancer clinicaltrials.gov\/ct2\/show\/NCT00191477"},{"issue":"4","key":"10.1002\/14651858.CD009294.pub3-BIB0008|cit8","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/S1569-9056(09)60644-8","article-title":"Gemcitabine versus BCG after initial BCG failure in non muscle-invasive bladder cancer: a prospective randomized trial","volume":"8","author":"Autorino","year":"2009","journal-title":"European Urology Supplements"},{"issue":"8","key":"10.1002\/14651858.CD009294.pub3-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1002\/cncr.24914","article-title":"Gemcitabine versus Bacille Calmette-Guerin after initial Bacille Calmette-Guerin failure in non-muscle-invasive bladder cancer: a multicenter prospective randomized trial","volume":"116","author":"Di Lorenzo","year":"2010","journal-title":"Cancer"},{"issue":"1","key":"10.1002\/14651858.CD009294.pub3-BIB0010|cit10","doi-asserted-by":"publisher","first-page":"e966","DOI":"10.1016\/S1569-9056(12)60963-4","article-title":"Is there a difference in quality of life between BCG and intravesical chemotherapy? Results of a randomized phase II study","volume":"11","author":"Gontero","year":"2012","journal-title":"European Urology Supplements"},{"issue":"4s","key":"10.1002\/14651858.CD009294.pub3-BIB0011|cit11","doi-asserted-by":"publisher","first-page":"e218","DOI":"10.1016\/j.juro.2012.02.604","article-title":"Is there a difference in quality of life between BCG and intravesical chemotherapy? Results of a randomized phase II study","volume":"187","author":"Gontero","year":"2012","journal-title":"Journal of Urology"},{"issue":"5","key":"10.1002\/14651858.CD009294.pub3-BIB0012|cit12","first-page":"1908","article-title":"Is there a difference in quality of life between intravesical chemotherapy and BCG? Results of a randomized phase II trial","volume":"32","author":"Gontero","year":"2012","journal-title":"Anticancer Research"},{"issue":"3","key":"10.1002\/14651858.CD009294.pub3-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/j.juro.2013.03.097","article-title":"The impact of intravesical gemcitabine and 1\/3 dose Bacillus Calmette-Gu\u00e9rin instillation therapy on the quality of life in patients with non-muscle invasive bladder cancer: results of a prospective, randomized, phase II trial","volume":"190","author":"Gontero","year":"2013","journal-title":"Journal of Urology"},{"key":"10.1002\/14651858.CD009294.pub3-BIB0014|cit14","unstructured":"The impact of intravesical gemcitabine and 1\/3 dose Bacillus Calmette-Guerin on the quality of life in superficial bladder cancer clinicaltrials.gov\/ct2\/show\/study\/NCT01697306"},{"issue":"4s","key":"10.1002\/14651858.CD009294.pub3-BIB0015|cit15","doi-asserted-by":"publisher","first-page":"e914","DOI":"10.1016\/j.juro.2017.03.036","article-title":"A phase III blinded study of immediate post-TURBT instillation of gemcitabine versus saline in patients with newly diagnosed or occasionally recurring grade I\/II non-muscle invasive bladder cancer: SWOG S0337","volume":"197","author":"Messing","year":"2017","journal-title":"Journal of Urology"},{"issue":"18","key":"10.1002\/14651858.CD009294.pub3-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1001\/jama.2018.4657","article-title":"Effect of intravesical instillation of gemcitabine vs saline immediately following resection of suspected low-grade non-muscle-invasive bladder cancer on tumor recurrence: SWOG S0337 randomized clinical trial","volume":"319","author":"Messing","year":"2018","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD009294.pub3-BIB0017|cit17","unstructured":"S0337, Gemcitabine after surgery in treating patients with newly diagnosed or recurrent bladder cancer clinicaltrials.gov\/ct2\/show\/study\/NCT00445601"},{"key":"10.1002\/14651858.CD009294.pub3-BIB0018|cit18","unstructured":"Bacillus of calmette and guerin (BCG) versus gemcitabine for intravesical therapy in high risk superficial bladder cancer clinicaltrials.gov\/ct2\/show\/study\/NCT00696579"},{"issue":"1","key":"10.1002\/14651858.CD009294.pub3-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1159\/000273461","article-title":"Bacillus Calmette-Guerin versus gemcitabine for intravesical therapy in high-risk superficial bladder cancer: a randomised prospective study","volume":"84","author":"Porena","year":"2010","journal-title":"Urologia Internationalis"},{"issue":"3","key":"10.1002\/14651858.CD009294.pub3-BIB0020|cit20","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1016\/j.juro.2010.05.060","article-title":"Single postoperative instillation of gemcitabine in patients with non-muscle-invasive transitional cell carcinoma of the bladder: a randomised, double-blind, placebo-controlled phase III multicentre study","volume":"184","author":"B\u00f6hle","year":"2010","journal-title":"Journal of Urology"},{"issue":"4","key":"10.1002\/14651858.CD009294.pub3-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1159\/000331727","article-title":"Can gemcitabine instillation ablate solitary low-risk non-muscle-invasive bladder cancer? Results of a phase II marker lesion study","volume":"87","author":"Brausi","year":"2011","journal-title":"Urologia Internationalis"},{"issue":"5","key":"10.1002\/14651858.CD009294.pub3-BIB0022|cit22","first-page":"385","article-title":"Evaluation of the efficacy and safety of intravesical instillation with gemcitabine after first-line intravesical chemotherapy failure in the treatment of non-muscle-invasive bladder cancer","volume":"33","author":"Cao","year":"2011","journal-title":"Zhonghua Zhong Liu za Zhi [Chinese Journal of Oncology]"},{"issue":"18","key":"10.1002\/14651858.CD009294.pub3-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"2729","DOI":"10.1200\/JCO.2005.05.2720","article-title":"Phase II trial of intravesical gemcitabine in bacille Calmette-Guerin-refractory transitional cell carcinoma of the bladder","volume":"24","author":"Dalbagni","year":"2006","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD009294.pub3-BIB0024|cit24","first-page":"109","article-title":"Curative effect analysis of different chemotherapeutics at intravesical instillation in the prevention of tumor recurrence after TUR-Bt","volume":"1","author":"Dong","year":"2017","journal-title":"Zhejiang Journal of Traumatic Surgery"},{"issue":"4s","key":"10.1002\/14651858.CD009294.pub3-BIB0025|cit25","doi-asserted-by":"publisher","first-page":"e1230","DOI":"10.1016\/j.juro.2018.02.2997","article-title":"Immediate post TURB intravesical gemcitabine: a cost comparison based on SWOG S0337","volume":"199","author":"Gantz","year":"2018","journal-title":"Journal of Urology"},{"issue":"3","key":"10.1002\/14651858.CD009294.pub3-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.urology.2005.03.084","article-title":"Randomized phase II marker lesion study evaluating effect of scheduling on response to intravesical gemcitabine in recurrent stage Ta urothelial cell carcinoma of the bladder","volume":"66","author":"Gardmark","year":"2005","journal-title":"Urology"},{"key":"10.1002\/14651858.CD009294.pub3-BIB0027|cit27","first-page":"118","article-title":"Comparison of the efficacy of different chemotherapy drugs in the prevention of postoperative recurrence in superficial bladder cancer by intravesical instillation","volume":"34","author":"Lin","year":"2016","journal-title":"China Foreign Medical Treatment"},{"key":"10.1002\/14651858.CD009294.pub3-BIB0028|cit28","first-page":"3238","article-title":"Comparison of intravesical perfusion of gemcitabine and mitomycin after non-muscle invasive bladder cancer","volume":"29","author":"Sun","year":"2016","journal-title":"Journal of Medical Theory and Practice"},{"issue":"5","key":"10.1002\/14651858.CD009294.pub3-BIB0029|cit29","doi-asserted-by":"publisher","first-page":"789","DOI":"10.3969\/j.issn.2095-1264.2019.05.18","article-title":"Effect of gemcitabine intravesical instillation in patients with bladder cancer and its influence on survival","volume":"9","author":"Xia","year":"2019","journal-title":"Anti-Tumor Pharmacy"},{"key":"10.1002\/14651858.CD009294.pub3-BIB0030|cit30","first-page":"1043","article-title":"Clinical effect of antineoplastic drug perfusion in preventing postoperative recurrence of superficial bladder cancer","volume":"17","author":"Xiaohong","year":"2015","journal-title":"J Chin Physician"},{"key":"10.1002\/14651858.CD009294.pub3-BIB0031|cit31","unstructured":"The randomized controlled study for intravesical instillation of Pseudomonas aeruginosa and gemcitabine in the prevention of postoperative recurrence of non-muscle invasive bladder cancer chictr.org.cn\/showproj.aspx?proj=44307"},{"key":"10.1002\/14651858.CD009294.pub3-BIB0032|cit32","unstructured":"A randomized study comparing single agent gemcitabine intravesical therapy versus mitomycin C in patients with intermediate risk superficial bladder cancer clinicaltrials.gov\/ct2\/show\/NCT00192049"},{"key":"10.1002\/14651858.CD009294.pub3-BIB0033|cit33","unstructured":"The bladder instillation comparison study (BIC) clinicaltrials.gov\/ct2\/show\/NCT02695771"},{"key":"10.1002\/14651858.CD009294.pub3-BIB0034|cit34","unstructured":"A study of erdafitinib versus investigator choice of intravesical chemotherapy in participants who received Bacillus Calmette-Gu\u00e9rin (BCG) and recurred with high risk non-muscle-invasive bladder cancer (NMIBC) clinicaltrials.gov\/ct2\/show\/NCT04172675"},{"issue":"6 Suppl","key":"10.1002\/14651858.CD009294.pub3-BIB0035|cit35","doi-asserted-by":"publisher","first-page":"TPS603","DOI":"10.1200\/JCO.2020.38.6_suppl.TPS603","article-title":"A randomized phase II study of erdafitinib (ERDA) versus intravesical chemotherapy (IC) in patients with high-risk nonmuscle invasive bladder cancer (HR-NMIBC) with FGFR mutations or fusions, who recurred after Bacillus Calmette-Guerin (BCG) therapy","volume":"38","author":"Steinberg","year":"2020","journal-title":"Journal of Clinical Oncology"},{"issue":"5","key":"10.1002\/14651858.CD009294.pub3-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.eururo.2019.08.016","article-title":"European Association of Urology Guidelines on non-muscle-invasive bladder cancer (TaT1 and carcinoma in situ) \u2013 2019 update","volume":"76","author":"Babjuk","year":"2019","journal-title":"European Urology"},{"issue":"6","key":"10.1002\/14651858.CD009294.pub3-BIB0037|cit37","first-page":"394","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA: a Cancer Journal for Clinicians"},{"issue":"4","key":"10.1002\/14651858.CD009294.pub3-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.eururo.2007.12.026","article-title":"Prediction of progression of non-muscle-invasive bladder cancer by WHO 1973 and 2004 grading and by FGFR3 mutation status: a prospective study","volume":"54","author":"Burger","year":"2008","journal-title":"European Urology"},{"issue":"4","key":"10.1002\/14651858.CD009294.pub3-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.juro.2016.06.049","article-title":"Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA\/SUO Guideline","volume":"196","author":"Chang S","year":"2016","journal-title":"J Urol"},{"key":"10.1002\/14651858.CD009294.pub3-BIB0040|cit40","unstructured":"Covidence Veritas Health Innovation 2017"},{"issue":"9","key":"10.1002\/14651858.CD009294.pub3-BIB0041|cit41","first-page":"2629","article-title":"Toxicology and pharmacokinetics of intravesical gemcitabine: a preclinical study in dogs","volume":"5","author":"Cozzi","year":"1999","journal-title":"Clinical\u00a0Cancer Research"},{"key":"10.1002\/14651858.CD009294.pub3-BIB0042|cit42","unstructured":"National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/CTCAE_v5_Quick_Reference_8.5x11.pdf"},{"key":"10.1002\/14651858.CD009294.pub3-BIB0043|cit43","unstructured":"Deeks JJ Higgins JP Altman DG Cochrane Statistical Methods Group Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JP, Churchill R, Chandler J, Cumpston MS, editor(s), Cochrane Handbook for Systematic Reviews of Interventions Version 5.2.0 (updated June 2017), Cochrane, 2017 Available from training.cochrane.org\/handbook\/archive\/v5.2"},{"issue":"8","key":"10.1002\/14651858.CD009294.pub3-BIB0044|cit44","first-page":"507","article-title":"Bladder cancer: diagnosis and treatment","volume":"96","author":"DeGeorge","year":"2017","journal-title":"American Family Physician"},{"key":"10.1002\/14651858.CD009294.pub3-BIB0045|cit45","unstructured":"EndNote Clarivate Analytics 2016"},{"issue":"12","key":"10.1002\/14651858.CD009294.pub3-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1097\/00000478-199812000-00001","article-title":"The World Health Organization\/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee","volume":"22","author":"Epstein","year":"1998","journal-title":"American Journal of Surgical Pathology"},{"issue":"2","key":"10.1002\/14651858.CD009294.pub3-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.ucl.2013.01.005","article-title":"Side effects of perioperative intravesical treatment and treatment strategies for these side effects","volume":"40","author":"Griffin","year":"2013","journal-title":"Urologic Clinics of North America"},{"issue":"7651","key":"10.1002\/14651858.CD009294.pub3-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1136\/bmj.39490.551019.BE","article-title":"What is \"quality of evidence\" and why is it important to clinicians?","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"issue":"4","key":"10.1002\/14651858.CD009294.pub3-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jclinepi.2010.04.026","article-title":"GRADE guidelines: 1. Introduction \u2013 GRADE evidence profiles and summary of findings tables","volume":"64","author":"Guyatt","year":"2011","journal-title":"Journal of Clinical Epidemiology"},{"issue":"2","key":"10.1002\/14651858.CD009294.pub3-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.eururo.2012.10.008","article-title":"A contemporary update on pathology standards for bladder cancer: transurethral resection and radical cystectomy specimens","volume":"63","author":"Hansel","year":"2013","journal-title":"European Urology"},{"issue":"5","key":"10.1002\/14651858.CD009294.pub3-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"377","DOI":"10.3109\/21681805.2015.1026937","article-title":"Bladder cancer detection in patients with gross haematuria: computed tomography urography with enhancement-triggered scan versus flexible cystoscopy","volume":"49","author":"Helenius","year":"2015","journal-title":"Scandinavian Journal of Urology"},{"issue":"11","key":"10.1002\/14651858.CD009294.pub3-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Higgins","year":"2002","journal-title":"Statistics in Medicine"},{"issue":"7414","key":"10.1002\/14651858.CD009294.pub3-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD009294.pub3-BIB0054|cit54","unstructured":"Higgins JP Deeks JJ Altman DG Cochrane Statistical Methods Group Chapter 16: Special topics in statistics. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from training.cochrane.org\/handbook\/archive\/v5.1\/"},{"key":"10.1002\/14651858.CD009294.pub3-BIB0055|cit55","unstructured":"Higgins JP Churchill R Chandler J Cumpston MS Cochrane Handbook for Systematic Reviews of Interventions Version 5.2.0 (updated June 2017), Cochrane, 2017 Available from training.cochrane.org\/handbook\/archive\/v5.2"},{"key":"10.1002\/14651858.CD009294.pub3-BIB0056|cit56","unstructured":"Higgins JP Altman DG Sterne JA Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Churchill R, Chandler J, Cumpston MS, editor(s), Cochrane Handbook for Systematic Reviews of Interventions Version 5.2.0 (updated June 2017), Cochrane, 2017 Available from training.cochrane.org\/handbook\/archive\/v5.2"},{"key":"10.1002\/14651858.CD009294.pub3-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1471-2288-5-13","article-title":"Estimating the mean and variance from the median, range, and the size of a sample","volume":"5","author":"Hozo","year":"2005","journal-title":"BMC Medical Research Methodology"},{"issue":"1","key":"10.1002\/14651858.CD009294.pub3-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.eururo.2016.02.028","article-title":"The 2016 WHO classification of tumours of the urinary system and male genital organs \u2013 Part B: prostate and bladder tumours","volume":"70","author":"Humphrey","year":"2016","journal-title":"European Urology"},{"issue":"10061","key":"10.1002\/14651858.CD009294.pub3-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"2796","DOI":"10.1016\/S0140-6736(16)30512-8","article-title":"Bladder cancer","volume":"388","author":"Kamat","year":"2016","journal-title":"Lancet"},{"issue":"3","key":"10.1002\/14651858.CD009294.pub3-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.euo.2020.02.006","article-title":"Evidence-based assessment of current and emerging bladder-sparing therapies for non-muscle-invasive bladder cancer after Bacillus Calmette-Guerin therapy: a systematic review and meta analysis","volume":"3","author":"Kamat","year":"2020","journal-title":"European Urology Oncology"},{"issue":"6","key":"10.1002\/14651858.CD009294.pub3-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1097\/00001813-200207000-00002","article-title":"Selective cytotoxicity of gemcitabine in bladder cancer cell lines","volume":"13","author":"Kilani","year":"2002","journal-title":"Anticancer Drugs"},{"issue":"1","key":"10.1002\/14651858.CD009294.pub3-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.juro.2013.07.102","article-title":"Defining progression in non-muscle invasive bladder cancer: it is time for a new, standard definition","volume":"191","author":"Lamm","year":"2014","journal-title":"Journal of Urology"},{"issue":"4","key":"10.1002\/14651858.CD009294.pub3-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1200\/JCO.2003.09.028","article-title":"Intravesical gemcitabine therapy for superficial transitional cell carcinoma of the bladder: a phase I and pharmacokinetic study","volume":"21","author":"Laufer","year":"2003","journal-title":"Journal of Clinical Oncology"},{"issue":"1","key":"10.1002\/14651858.CD009294.pub3-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/s12894-020-00610-9","article-title":"Intravesical gemcitabine versus mitomycin for non-muscle invasive bladder cancer: a systematic review and meta-analysis of randomized controlled trial","volume":"20","author":"Li","year":"2020","journal-title":"BMC Urology"},{"issue":"3","key":"10.1002\/14651858.CD009294.pub3-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.eururo.2020.02.012","article-title":"Systematic review of the therapeutic efficacy of bladder-preserving treatments for non-muscle-invasive bladder cancer following intravesical Bacillus Calmette-Gu\u00e9rin","volume":"78","author":"Li","year":"2020","journal-title":"European Urology"},{"issue":"7","key":"10.1002\/14651858.CD009294.pub3-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"e1000100","DOI":"10.1371\/journal.pmed.1000100","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration","volume":"6","author":"Liberati","year":"2009","journal-title":"PLoS Medicine"},{"issue":"5","key":"10.1002\/14651858.CD009294.pub3-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1016\/j.urology.2009.05.094","article-title":"Systemic absorption and pharmacokinetics of single-dose intravesical gemcitabine after transurethral resection of the bladder in non-muscle-invasive bladder cancer","volume":"74","author":"Maffezzini","year":"2009","journal-title":"Urology"},{"key":"10.1002\/14651858.CD009294.pub3-BIB0068|cit68","unstructured":"MedCalc Statistical Software MedCalc Software bvba"},{"key":"10.1002\/14651858.CD009294.pub3-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"v7","DOI":"10.1093\/annonc\/mdj941","article-title":"Cellular pharmacology of gemcitabine","volume":"17 Suppl 5","author":"Mini","year":"2006","journal-title":"Annals of Oncology"},{"key":"10.1002\/14651858.CD009294.pub3-BIB0070|cit70","unstructured":"National Comprehensive Cancer Network Bladder cancer, NCCN clinical practice guidelines in oncology www.nccn.org\/professionals\/physician_gls\/default.aspx#site"},{"issue":"1","key":"10.1002\/14651858.CD009294.pub3-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1200\/JCO.1998.16.1.139","article-title":"Interpreting the significance of changes in health-related quality-of-life scores","volume":"16","author":"Osoba","year":"1998","journal-title":"Journal of Clinical Oncology"},{"issue":"24","key":"10.1002\/14651858.CD009294.pub3-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1002\/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8","article-title":"Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints","volume":"17","author":"Parmar","year":"1998","journal-title":"Statistics in Medicine"},{"issue":"3","key":"10.1002\/14651858.CD009294.pub3-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.eururo.2013.06.009","article-title":"Immediate post-transurethral resection of bladder tumor intravesical chemotherapy prevents non-muscle-invasive bladder cancer recurrences: an updated meta-analysis on 2548 patients and quality-of-evidence review","volume":"64","author":"Perlis","year":"2013","journal-title":"European Urology"},{"issue":"10","key":"10.1002\/14651858.CD009294.pub3-BIB0074|cit74","first-page":"2017","article-title":"Updates on the use of intravesical therapies for non-muscle invasive bladder cancer: how, when and what","volume":"37","author":"Peyton","year":"2019","journal-title":"World Journal of\u00a0Urology"},{"key":"10.1002\/14651858.CD009294.pub3-BIB0075|cit75","unstructured":"Review Manager 5 (RevMan 5) Nordic Cochrane Centre, The Cochrane Collaboration 2014"},{"issue":"4","key":"10.1002\/14651858.CD009294.pub3-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1097\/MOU.0000000000000769","article-title":"Bladder-preserving strategies for Bacillus Calmette-Gu\u00e9rin unresponsive non-muscle invasive bladder cancer; where are we and what will be expected?","volume":"30","author":"Sari Motlagh","year":"2020","journal-title":"Current Opinion in Urology"},{"issue":"1","key":"10.1002\/14651858.CD009294.pub3-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1002\/jrsm.1078","article-title":"Non-randomized studies as a source of complementary, sequential or replacement evidence for randomized controlled trials in systematic reviews on the effects of interventions","volume":"4","author":"Sch\u00fcnemann","year":"2013","journal-title":"Research Synthesis Methods"},{"key":"10.1002\/14651858.CD009294.pub3-BIB0078|cit78","unstructured":"Sch\u00fcnemann HJ Oxman AD Higgins JP Vist GE Glasziou P Akl E Cochrane GRADEing Methods Group and the Cochrane Statistical Methods Group Chapter 11: Completing 'Summary of findings' tables and grading the confidence in or quality of the evidence. In: Higgins JP, Churchill R, Chandler J, Cumpston MS, editor(s),Cochrane Handbook for Systematic Reviews of Interventions Version 5.2.0 (updated June 2017). Cochrane, 2017 Available from training.cochrane.org\/handbook\/archive\/v5.2"},{"issue":"1","key":"10.1002\/14651858.CD009294.pub3-BIB0079|cit79","first-page":"7","article-title":"Cancer statistics, 2020","volume":"70","author":"Siegel","year":"2020","journal-title":"CA: a Cancer Journal for Clinicians"},{"issue":"1 Suppl 2","key":"10.1002\/14651858.CD009294.pub3-BIB0080|cit80","first-page":"31","article-title":"Gemcitabine in bladder cancer","volume":"27","author":"Sternberg","year":"2000","journal-title":"Seminars in Oncology"},{"issue":"3","key":"10.1002\/14651858.CD009294.pub3-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.eururo.2005.12.031","article-title":"Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials","volume":"49","author":"Sylvester","year":"2006","journal-title":"European Urology"},{"key":"10.1002\/14651858.CD009294.pub3-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1745-6215-8-16","article-title":"Practical methods for incorporating summary time-to-event data into meta-analysis","volume":"8","author":"Tierney","year":"2007","journal-title":"Trials"},{"key":"10.1002\/14651858.CD009294.pub3-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"4641","DOI":"10.2147\/OTT.S170477","article-title":"The efficacy and safety of intravesical gemcitabine vs Bacille Calmette-Guerin for adjuvant treatment of non-muscle invasive bladder cancer: a meta-analysis","volume":"11","author":"Ye","year":"2018","journal-title":"OncoTargets and Therapy"},{"issue":"10","key":"10.1002\/14651858.CD009294.pub3-BIB0084|cit84","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009294","article-title":"Intravesical gemcitabine for non-muscle invasive bladder cancer","author":"Jones","year":"2011","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD009294.pub3-BIB0085|cit85","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009294.pub2","article-title":"Intravesical gemcitabine for non-muscle invasive bladder cancer","author":"Jones","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T12:19:00Z","timestamp":1776428340000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD009294.pub3"}},"subtitle":[],"editor":[{"name":"Cochrane Urology Group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2021,6,14]]},"references-count":85,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2021,6]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd009294.pub3","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,14]]}}}